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INTRODUCTION
The use of transcatheter aortic valve replacement (TAVR) in pa-
tients with severe aortic stenosis (AS) who are ineligible for or 
are at high risk for surgical aortic valve replacement (sAVR) has 
increased exponentially since it was first introduced in 2002.1 
To date, TAVR has been reported to result in a prompt decrease 
in left ventricular (LV) afterload2 without the disturbing effects 
of major surgery and clinical improvement in severe symp-
tomatic AS.3-5  Notwithstanding, although the impact of sAVR 
or TAVR on LV function has been studied using various imag-
ing modalities, the effects of TAVR on diastolic function remain 
controversial,2,6-8 and data are limited on the effect of TAVR on 
serial changes in LV diastolic function during follow-up imme-
diate and early after the procedure. This study aimed to assess 
and compare the effects of TAVR and sAVR on recovery of LV 
diastolic function in patients with symptomatic severe AS 
through serial echocardiographic examinations prior to, im-
mediately after, and 3 months after the procedures.
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Purpose: We aimed to compare the effect of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement 
(sAVR) on recovery of left ventricular (LV) diastolic function and afterload through serial echocardiographic examinations in pa-
tients with symptomatic high-risk severe aortic stenosis during early follow-up. 
Materials and Methods: We included 38 patients undergoing TAVR (mean age, 80±6 years; male:female=18:20) and 27 patients 
undergoing sAVR (mean age, 78±3 years; male:female=12:15). We compared changes in the LV diastolic function and afterload 
before, immediately after, and 3 months after the procedure using serial transthoracic echocardiography.
Results: Immediately after the procedure, 16 (42%) and 3 (11%) patients in the TAVR and sAVR groups, respectively, showed rapid 
improvement in diastolic filling patterns. E wave to e' ratio (E/e') and right ventricular systolic pressure (RVSP) decreased signifi-
cantly in the TAVR group (E/e': TAVR, from 24.6±12.9 to 20±9.5, p=0.048 vs. sAVR, from 21.5±9.4 to 20.64±6.4, p=0.361; RVSP: TAVR, 
38.4±17.2 vs. 34±12.4, p=0.032 vs. sAVR, 32.2±11.7 vs. 30±6.8, p=0.27). After 3 months, diastolic grade distribution, E/e', and RVSP 
were similar. Valvuloarterial impedance significantly decreased immediately after the procedure in both groups (TAVR, from 
5.1±1.4 to 3.1±1.0 vs. sAVR, from 4.5±1.5 to 3.1±0.8 mm Hg . mL−1 . m−2, p=0.001), but after 3 months, decreases were greater in the 
sAVR group (from 3.1±0.8 to 2.2±1.5 mm Hg . mL−1 . m−2, p=0.093). 
Conclusion: LV diastolic function improved more rapidly and earlier in patients treatment with TAVR than in patients treated with 
sAVR. These results might explicate the remarkable clinical improvement in improvements in advanced diastolic dysfunction im-
mediately after the TAVR procedure than sAVR.
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MATERIALS AND METHODS
Study population
We consecutively enrolled 38 patients with symptomatic se-
vere AS who underwent transfemoral TAVR between 2011 and 
2013 at our institute (TAVR group). We also enrolled 27 patients 
who were older than 75 years and underwent sAVR during the 
same period. The TAVR group consisted of patients treated with 
TAVR if their aortic valve area was <1 cm2, their European Sys-
tem for Cardiac Operative Risk Evaluation score (EuroSCORE) 
was >20%, or their EuroSCORE was ≤20% and the following 
criteria were met: contraindicated for surgery, severely reduced 
pulmonary function (defined as forced expiratory volume in 1 
second <1 L), liver cirrhosis (Child A or B), and severe pulmo-
nary hypertension (pulmonary systolic pressure > 60 mm Hg). 
Exclusion criteria included: known contraindications to anti-
platelet agents or anticoagulant therapy, allergic reaction to 
nitinol or contrast media that could not be premedicated, any 
sepsis, history of AVR, any condition considered a contraindi-
cation to extracorporeal assistance, symptomatic carotid or 
vertebral artery disease (>70% stenosis), abdominal aortic an-
eurysm, bleeding diathesis or coagulopathy, creatinine clear-
ance <20 mL/min, and life expectancy <1 year. Patients with 
significant coronary artery disease were completely revascu-
larized by percutaneous coronary intervention before TAVR.
All 38 patients in the TAVR group and 27 patients in the sAVR 
group exhibited New York Heart Association (NYHA) func-
tional class ≥II symptoms, and their echocardiographic find-
ings were consistent with severe AS (aortic valve area <1 cm2 
with or without a transvalvular mean pressure gradient ≥40 
mm Hg).9 The decision for TAVR or sAVR was made for each 
patient based on clinical symptom severity combined with co-
morbid disease, physical performance status, and echocar-
diography parameters. The patients were selected for TAVR af-
ter they were considered inoperable or at high risk as assessed 
by a multispecialty team. 
TAVR was executed with fluoroscopy and transesophageal 
echocardiography guidance under general anesthesia using 
standard techniques.10 Pre-procedural echocardiography and 
multi-slice computed tomography were used to measure aor-
tic annulus size. Immediately after prosthetic valve deploy-
ment, transesophageal echocardiography was performed to 
confirm good motion of the prosthetic valve and identify any 
paravalvular leakage.
Echocardiographic and doppler measurements
All patients were investigated using two-dimensional trans-
thoracic echocardiography (TTE) before the procedure (TAVR 
or sAVR), immediately after the procedure, and 3 months after 
the procedure. In the TAVR group, TTE follow-up was per-
formed 1 day after the procedure. The short-term effects of 
sAVR were evaluated using echocardiography 5–7 days after 
the procedure. 
Standard two-dimensional pulsed-wave Doppler and pulsed-
wave Doppler tissue imaging (DTI) echocardiographic param-
eters were collected from parasternal and apical acoustic win-
dows based on American Society of Echocardiography (ASE) 
guidelines11 using an IE33 (Phillips, Andover, MA, USA) or viv-
id E9 (Vinmed; General Electric, Milwaukee, WI, USA). All pa-
tients were investigated in the left lateral supine position under 
electrocardiographic monitoring. 
M-mode tracing obtained just below the mitral valve leaflets 
was acquired in the parasternal short-axis view. We measured 
LV end-diastolic (LVED) and end-systolic (LVES) dimensions, 
such as interventricular septal wall thickness, posterior wall 
thickness, and LVED and LVES diameters.12 LVED and LVES 
volumes were acquired from apical two- and four-chamber 
views using the biplane modified Simpson’s rule, while LV 
ejection fraction (EF) was calculated according to ASE recom-
mendations.12 LA volume indices (LAVI) were also measured 
using the biplane Simpson’s method. LV mass was calculated 
using the Devereux formula and indexed to body surface area 
calculated using the Mosteller formula. Relative wall thickness 
(RWT) was calculated as 2×LV diastolic posterior wall thick-
ness/LVED diameter and was regarded as abnormal when 
>0.42. Relative wall thickness and LV mass index (LVMI) were 
applied to evaluate LV geometry. 
Continuous-wave Doppler examinations were evaluated for 
peak instantaneous velocity. The mean and maximum aortic 
valve pressure gradients were assessed for all patients using 
the modified Bernoulli equation with flow velocity-time inte-
grals over the ejection period in continuous-wave Doppler re-
cordings with a 100 mm/s time scale. Aortic valve area was 
calculated using the continuity equation following ASE rec-
ommendations.13 Aortic and mitral regurgitation were evalu-
ated based on ASE recommendations.14
LV filling variables were achieved from pulsed-wave Dop-
pler recordings of transmitral flow velocity. The sample vol-
ume was allocated at the tips of the mitral valve leaflets. Dop-
pler velocity recordings of three cardiac cycles at a paper speed 
of 100 mm/s were digitized, and the variables were averaged. 
LV diastolic function was evaluated using pulsed-wave Dop-
pler and pulsed-wave DTI recordings based on ASE/European 
Association of Cardiovascular Imaging recommendations.15 
Transmitral flow was attained to gather peak early (E) and atri-
al (A) flow velocities. We used the mean peak early diastolic (e') 
velocity obtained from the septal side of the mitral annulus in 
the four-chamber view with appropriate DTI settings. Systolic 
(s') and late diastolic velocity (a') and isovolumic relaxation 
time were computed utilizing pulsed-wave DTI at the septal 
insertion sites of the mitral leaflets in the apical four-chamber 
view. The E wave to e’ ratio (E/e') was calculated to determine 
LV filling pressures. Tricuspid regurgitation pressure gradient 
was measured on color-flow Doppler imaging using paraster-
nal RV inflow view. 
Accordingly, diastolic function was determined based on the 
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2016 recommendations.15 Diastolic function was then classified 
into grade I, grade II, grade III, and indeterminate/normal 
grade considering early-late ventricular filling velocities (E/A) 
ratio, E/e' ratio, tricuspid regurgitation velocity, and LAVI. In 
patients with indeterminate grade diastolic dysfunction and 
depressed LV ejection fraction (LVEF), the systolic/diastolic 
pulmonary venous flow velocity ratio was utilized.
Arterial hemodynamics and global LV afterload
Systolic and diastolic blood pressure was estimated utilizing 
an arm-cuff sphygmomanometer at the time of the Doppler 
echocardiography examination. To assess the elastic proper-
ties of the ascending aorta, the systolic and diastolic aortic di-
ameters were evaluated 1 cm above the sinotubular junction 
by two-dimensionally guided M-mode transthoracic echocar-
diography in the parasternal long-axis view.16 The ratio of stroke 
volume index to brachial pulse pressure (the difference between 
systolic and diastolic blood pressure) was utilized as an indirect 
measure of total systemic arterial compliance (SAC).17 Sys-
temic vascular resistance (SVR) was determined by the follow-
ing formula: (80×MAP)/CO, where MAP is the mean arterial 
pressure and CO is the cardiac output.17 To assess global LV af-
terload, valvuloarterial impedance (Zva) was computed as the 
sum of the systolic arterial pressure and the mean transvalvu-
lar pressure gradient divided by the stroke volume index.18
Statistical analysis
Continuous variables are expressed as means±standard devi-
ations, while categorical variables are expressed as frequencies 
and percentages. Statistics were calculated using SPSS version 
19.0 (IBM Corp., Armonk, NY, USA). Intergroup comparisons 
were undertaken utilizing a two-tailed Student’s t test or Welch 
test and non-parametric methods depending on the data dis-
tribution. Categorical variables were compared utilizing Fisher’s 
exact test. Since diastolic function grade was an ordinal variable, 
comparisons involving this variable utilized the exact Jonck-
heere-Terpstra test. We performed a repeated-measured anal-
ysis of variance to determine differences between groups and 
over time. p values <0.05 were considered statistically significant.
RESULTS
Baseline clinical characteristics and echocardiography
findings
The baseline patient characteristics are presented in Table 1. 
We included 38 patients who underwent TAVR (TAVR group: 
mean age, 80±6 years, male:female=18:20) and 27 patients 
who were older than 75 years and underwent sAVR during the 
same period (sAVR group: mean age, 78±3 years, male:female 
=12:15). A CoreValve (Medtronic CoreValve Percutaneous Sys-
tem; Medtronic Inc., Minneapolis, MN, USA) was inserted in all 
patients in the TAVR group. As expected, the Society of Thorac-
ic Surgeons risk score (8.7±4.2 vs. 5.8±4.3, p=0.028) and logis-
tic EuroSCORE (25.8±16.9 vs. 13.8±13.0, p=0.011) in the TAVR 
group were higher than those in the sAVR group. Furthermore, 
patients in the TAVR group had a lower mean body mass in-
dex (TAVR, 21.1±3.3 vs. 23.9±3.3 kg/m2, p=0.002). There were 
trends toward more patients with chronic lung disease (40% vs. 
30%, p=0.290) and chronic kidney disease (estimated glomer-
ular filtration rate <60 mL/min/m2) in the TAVR group than in 
the sAVR group (47% vs. 33%, p=0.179) (Table 1). At baseline ex-
amination, the TAVR group consisted of 33 (87%) patients in 
sinus rhythm and 5 (13%) with atrial fibrillation (AF), whereas 
the sAVR group had 21 (79%) patients in sinus rhythm and 6 
(21%) with AF. The baseline echocardiographic findings are 
presented in Table 2. No significant intergroup differences 
were found in chamber size, geometry, and function, except 
for lower aortic valve area index, in the TAVR group (0.65±0.17 
vs. 0.77±0.22 cm2/m2, p=0.017).
In the sAVR group, all patients received a bioprosthesis (Car-
pentier Edwards Bioprosthesis in 13; Carpentier Edwards Peri-
mount Magna Bioprosthesis in 2; and Saint Jude epic Biopros-
thesis in 12). All surgical patients had a favorable postoperative 
state without any serious 30-day complications.
Hemodynamic improvement after TAVR and sAVR 
Early hemodynamic improvement was comparable between 
Table 1. Baseline Characteristics of the TAVR and sAVR Groups
 
TAVR group 
(n=38)
sAVR group 
(n=27)
p value
Clinical variables
Age (yr) 80±6 78±3 0.436
Men 18 (47) 12 (44) 0.612
Body mass index (kg/m2) 21.1±3.3 23.9±3.3 0.002*
NYHA class III or IV 29 (76) 22 (81) 0.548
Diabetes mellitus 13 (39) 8 (30) 0.320
Hypertension 24 (73) 16 (60) 0.551
Coronary heart disease 20 (52) 12(44) 0.511
Previous MI 5 (13) 1 (4) 0.163
Old CVA 6 (16) 2 (7) 0.220
Previous cardiac surgery 3 (8) 1 (4) 0.401
Previous AF Hx 5 (13) 6(19) 0.332
Chronic lung disease 15 (40) 8 (30) 0.290
CKD (eGFR<60 mL/min/m2) 18 (47) 9 (33) 0.179
Predicted operative mortality
STS score (%) 8.7±4.2  5.8±4.3 0.028*
Logistic EuroSCORE (%) 25.8±16.9 13.8±13.0 0.011*
TAVR, transcatheter aortic valve replacement; sAVR, surgical aortic valve re-
placement; STS, Society of Thoracic Surgeons; CVA, cerebrovascular accident; 
MI, myocardial infarction; PCI, percutaneous coronary intervention; OP, oper-
ation; Hx, history; AF, atrial fibrillation; CKD, chronic kidney disease; NYHA, New 
York Heart Association; eGFR, estimated glomerular filtration rate; EuroSCORE, 
European System for Cardiac Operative Risk Evaluation score.
Data are presented as means±standard deviations or n (%).
*p<0.05.
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the groups: peak AV velocity (AVmax: TAVR, from 4.6±0.9 to 2.1± 
0.5 vs. sAVR, from 4.4±0.7 to 2.6±0.4 m/s, p<0.001) (Table 3, Fig. 
1A) and mean systolic pressure gradient (MSPG: TAVR, 
from 54.4±18.5 to 11.1±5.2 vs. sAVR, from 48±17.1 to 16.3±5 
mm Hg, p<0.001) (Table 3, Fig. 1B). Moreover, these improve-
ments were maintained after 3 months without significant 
changes (Table 3, Fig. 1A). In addition, LVEF, SV, and cardiac 
index tended to increase in both groups over time after 3 months 
(LVEF: TAVR, from 61.4±15.2% to 64.9±8.9% vs. sAVR, from 
62.3±15% to 66.6±8.9%; SV: TAVR, from 67±15.2 to 69± 17.3 vs. 
sAVR, from 77±24.6 to 81±12 mL; cardiac index: TAVR, from 
3.2±0.9 to 3.2±0.9 vs. sAVR, from 3.5±0.9 to 3.5±1.2 L/min/m2, 
p=NS) (Table 3). In addition, we noted significant improve-
ments in s' velocity immediately after and 3 months after the 
procedure in both groups (TAVR, from 4.4± 1.3 to 5.5±1.8 vs. 
sAVR, from 4.8±1.1 to 5.9±1.5 cm/s, p=0.001) (Table 3).
Comparison of recovery of diastolic function after 
TAVR and sAVR during serial follow up 
Immediately after AVR, 16 patients (42%) showed improve-
ment in LV diastolic function grade in the TAVR group versus 
only 3 patients (11%) in the sAVR group. Early improvement in 
diastolic function grade was seen immediately after TAVR (p= 
0.018) (Fig. 2), but no further improvement was found after 3 
months. However, a small improvement was found immedi-
ately after sAVR (p=0.04) (Fig. 2), although no further improve-
ment was noted 3 months later (p=0.99) (Fig. 2). E velocity (from 
81.2±30.5 to 88.7±27.8 vs. from 79.8±29.4 to 91±21.4 cm/s, p= 
0.048) and e' velocity (from 3.6±1.2 to 4.4±1.4 vs. from 3.7±1.4 
to 4.5±1.5 cm/s, p=0.048) (Table 4, Fig. 3A and B) were signifi-
cantly increased in the TAVR group versus the sAVR group. 
Deceleration time (DT) increased significantly immediately 
after TAVR (from 210±64 to 229±69 ms, p=0.008) (Table 4), but 
only at 3 months after sAVR (204±61 vs. 261±80 ms, p=0.033) 
(Table 4). Unlike the sAVR group (from 21.5±9.4 to 20±6.4, 
p=0.361), E/e' ratio decreased significantly in the TAVR group 
immediately after the procedure (from 24.6±12.9 to 20 ±9.5, 
p=0.048) (Table 4, Fig. 3C). Moreover, immediately after the 
procedure, a significant decrease was found in right ventricu-
lar systolic pressure in the TAVR group, compared with the sAVR 
group (TAVR, 38.4±17.2 vs. 34±12.4, p=0.032 vs. sAVR, 32.2± 
11.7 vs. 30±6.8 mm Hg, p=0.27) (Table 4, Fig. 3D). 
Changes in global LV afterload after TAVR and sAVR 
Valvuloarterial impedance (Zva) was significantly decreased 
immediate after the procedure in both groups (from 5.1±1.4 
to 3.1±1.0 vs. from 4.5±1.5 to 3.1±0.8 mm Hg . mL−1 . m−2, p< 
0.001) (Fig. 4A) but a further decrease was observed only in 
the sAVR group (from 3.1±0.8 to 2.2±1.5 mm Hg . mL−1 . m−2, 
p=0.093) (Fig. 4A). In addition, SVR was significantly de-
creased immediately after the procedure (from 1044±628 to 
198±100 vs. from 747±270 to 214±76 dyne . s . cm−5, p=0.001) (Fig. 
4C), although no further decrease was noted 3 months later in 
either group. Although the SAC of TVAR was greater than that 
of sAVR at baseline (1.06±0.27 vs. 0.76±0.37 mL . mm Hg−1 . 
m−2, p=0.02) (Fig. 4B), there was no change in SAC immedi-
ately after the procedure or 3 months later in either group 
(from 0.76±0.37 to 0.7±0.29 vs. from 1.06±0.27 to 0.94±0.29 
mL . mm Hg−1 . m−2, p=0.295) (Fig. 4B). 
LA and LV structural changes after TAVR and sAVR 
In both groups, LV chamber size, including LV end-diastolic 
diameter (LVEDD), LV end-systolic diameter (LVESD), and the 
thicknesses of the septum and posterior wall, did not change 
significantly over time, except for LVEDD and LVESD at 3 
months after sAVR (LVEDD, from 49±7.8 to 45.4±4.5 mm; 
LVESD, from 33 ±8 to 30±4.9 mm, p<0.05, respectively) (Table 
Table 2. Baseline Echocardiographic Findings of the TAVR and sAVR 
Groups
 
TAVR group
(n=38)
sAVR group
(n=27)
p value
AVAI (cm2/m2) 0.65±0.17 0.77±0.22 0.017*
Doppler velocity index (LVOT/AV) 0.21±0.08 0.23±0.06 0.549
Peak PG (mm Hg) 86.3±30.4 78.9±27 0.294
Mean PG (mm Hg) 54.4±18.5 48±17.1 0.164
Stroke volume (mL) 67±15.2 77±24.6 0.051
LVEF (%) 61.4±15.2 62.3±15 0.806
Cardiac index (L/min/m2) 3.2±0.9 3.5±0.9 0.288
E velocity (cm/s) 83.4±37.1 79.8±29.4 0.682
A velocity (cm/s) 98.9±34.2 98.3±22.7 0.941
Deceleration time (ms) 210±64 205±45 0.584
e’ velocity (cm/s) 3.6±1.2 3.7±1.4 0.152
a’ velocity (cm/s) 6.9±2.5 7.2±1.7 0.724
s’ velocity (cm/s) 4.4±1.3 4.8±1.1 0.216
E/e’ ratio 24.6±12.9 21.5±9.4 0.307
RVSP (mm Hg) 39.8±16.2 34.5±12.4 0.162
HR (bpm) 72±16 73±19 0.825
SBP (mm Hg) 126±23 120±18 0.051
DBP (mm Hg) 68±11 68±11 0.872
LAVI (mL/m2) 43.3±16.7 51.1±22 0.128
LVEDD (mm) 48.7±7.7 49±7.8 0.972
LVESD (mm) 33.5±9.3 33±8 0.889
IVST (mm) 12.7±2.8 12±1.5 0.181
LVPWT (mm) 11.8±2.0 11.8±2.2 0.749
RWT 0.46±0.1 0.49±0.1 0.826
LVMI (g/m2) 159±48 146±40 0.259
TAVR, transcatheter aortic valve replacement; sAVR, surgical aortic valve re-
placement; LVOT, left ventricular outflow tract; AVAI, aortic valve area index; 
PG, pressure gradient; LVEF, left ventricular ejection fraction; E/e’, E wave to 
e’ ratio; RVSP, right ventricular systolic pressure; HR, heart rate; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; LAVI, left ventricular volume in-
dex; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular 
end-systolic diameter; IVST, interventricular septal thickness; LVPWT, left ven-
tricular posterior wall thickness; RWT, relative wall thickness; LVMI, left ven-
tricular mass index.
Data are presented as means±standard deviations.  
*p<0.05. 
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5). LV mass and LVMI were unchanged immediately after the 
procedures. Meanwhile, however, LVMI decreased significant-
ly and RWT tended to be lower 3 months after the procedures 
(LVMI: TAVR, from 159±48 to 148±48 vs. sAVR, from 146±41 to 
125±29 g/m2; RWT: TAVR, from 0.49±0.13 to 0.48±0.1 vs. sAVR, 
from 0.49±0.1 to 0.48±0.1, p=0.001 vs. p=NS) (Table 5). LAVI 
significantly changed only immediately after sAVR (from 
51.1±22 to 45.9± 17.4 mL/m2, p=0.015) (Table 5). 
Clinical outcomes
All sAVR and TAVR patients had a favorable postoperative 
course without any 30-day mortality. During the 3-year fol-
low-up period, 5 patients (13%) died in the TAVR group versus 
3 patients (11%) in the sAVR group (p=0.186). Stroke occurred 
in 3 patients (11%) in the sAVR versus no patients in the TAVR 
group (p=0.081). Major bleeding events developed in 5 pa-
tients (13%) in the TAVR group and 4 patients (15%) in the sAVR 
group (p=0.628). Complete atrioventricular block requiring 
permanent pacemaker insertion developed in 5 patients (13%) 
in the TAVR group and 2 (7%) in the sAVR group (p=0.341). 
There were 3 pericardial effusions (8%) in the TAVR group and 
1 episode of ventricular tachycardia requiring defibrillation in 
the sAVR group. There was a significant intergroup difference 
in the prevalence of clinically related pleural effusion (80% in 
the sAVR group vs. 29% in the TAVI group, p<0.001) immedi-
ately after the procedure. Post-procedurally, aortic regurgita-
tion was observed in 26 patients (68%) in the TAVR group only, 
the degrees of which were all less than moderate.
DISCUSSION
This study demonstrates the possible contrasting effects of TAVR 
and sAVR on diastolic function over time, especially those im-
Table 3. Hemodynamic Improvement after TAVR and sAVR
 
TAVR sAVR
Pre Immediate 3 months Pre Immediate 3 months
AVmax (m/s) 4.6±0.9 2.1±0.5* 2.1±0.5 4.4±0.7 2.6±0.4* 2.4±0.4 
Doppler velocity index (LVOT/AV) 0.21±0.08 0.62±0.14* 0.58±0.12 0.23±0.06 0.48±0.11* 0.51±0.16
Peak PG (mm Hg) 86.3±30.4 20.9±9.6* 18.6±8.4 78.9±27 29.5±8.38* 26.6±10.0 
Mean PG (mm Hg) 54.4±18.5 11.1±5.2* 9.6±5.0 48±17.1 16.3±5* 14.4±5.0 
Stroke volume (mL) 67±15.2 72±18.2 69±17.3 77±24.6 73±16 81±12
LVEF (%) 61.4±15.2 61.1±13.3 64.9±8.9 62.3±15 64.5±9.8 66.6±8.9
s’ velocity (cm/s) 4.4±1.3 5.5±1.8* 4.9±1.7 4.8±1.1 5.9±1.5* 5.4±1.0
Cardiac index (L/min/m2) 3.2±0.9 3.6±1.4 3.2±0.9 3.5±0.9 3.8±0.8 3.5±1.2
TAVR, transcatheter aortic valve replacement; sAVR, surgical aortic valve replacement; LVOT, left ventricular outflow tract; AVmax, peak aortic valve velocity; PG, 
pressure gradient; LVEF, left ventricular ejection fraction. 
Data are presented as means±standard deviations. 
*Effect between pre-procedure and immediate procedure: p<0.05
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Fig. 1. Hemodynamic changes over time. (A) Serial change of aortic valve peak velocity. (B) Serial change of MSPG across the aortic valve. Error bars rep-
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mediately after the procedure and 3 months later in cases of 
high-risk AS. We found more significant and earlier improve-
ment in diastolic function in the TAVR group versus the sAVR 
group. We noticed that this improvement was achieved through 
a marked decreased in PG across AV and led to an increase in 
E and e' velocity, elongation of DT, and a decrease in E/e' ra-
tio in the TAVR, compared the sAVR group. In result, there was 
an early and rapid recovery of diastolic grade distribution im-
mediately after the procedure in the TAVR group.
The major hemodynamic feature of AS is LV pressure over-
load. As a result of increased afterload and LV remodeling,19,20 
AS leads to LV diastolic dysfunction, increased filling pres-
sures, and heart failure symptoms. Diastolic dysfunction occurs 
even in the early disease course, followed by an increase in LV 
mass.21 As observed in other previous studies, after TAVR, our 
patients showed significant increases in effective orifice area 
with marked reductions in transvalvular pressure gradients 
equivalent to a reduction in LV afterload.2 Accordingly, E and 
e' reflecting early diastolic relaxation increased significantly 
and immediately after TAVR. These results are consistent with 
previously published data from Gonçalves, et al.2 and Guarrac-
ino, et al.,22 who calculated parameters of LV relaxation within 
minutes after TAVR. In our patients, DT also increased, suggest-
ing that LV chamber compliance improved immediately after 
TAVR due to a reduction in LV afterload. All of our patients ex-
hibited LV diastolic dysfunction before valve implantation, with 
grade II being the most prevalent (47.3%). Utilizing an integra-
tive approach focusing on e', E/A ratio, DT, and E/e' ratio, al-
most half of the patients (42%) in the TAVR group improved by 
at least one grade, compared with 11% in the sAVR group. This 
is because E wave velocity and DT increased which might be 
the consequence of increased relaxation and improved LV 
compliance due to almost complete normalization of the af-
terload. Interestingly, these effects were more prominent im-
mediately after TAVR than sAVR, and the differences therein 
may be explained by a higher-pressure gradient across AV and 
more marked reduction in PG versus sAVR. E/e' ratio, which is 
a parameter for the evaluation of LV filling pressure,23 slightly, 
but significantly, improved immediately after the procedure in 
only the TAVR group. The change in LA volume did not change, 
which supported the chronicity of diastolic dysfunction, and 
the procedure had no effect on LA volume in the TAVR group. 
In addition, change in LA size reflected the chronicity index for 
a long-term change. Our study population consisted of rela-
tively acute-phase patients (up to 3 months). Therefore, although 
LA size was one of the parameters of diastolic function, it did 
not change during the study period, although because our 
study had a small sample size and had a retrospective design, 
selection bias might have occurred. Notwithstanding, the acute 
recovery in diastolic function parameters found in our study 
is in accord with that seen in a previous study,2 although the 
previous study measured function parameters during the pro-
cedure and did not compare them with a surgical group. Our 
study aimed to compare the effects of TAVR and sAVR imme-
diately after the procedure and 3 months later based on trans-
thoracic echocardiography findings in order to reflect the real-
world situation of changes immediately after the procedure 
and the outpatient situation. 
Although sAVR is the conventional and reference treatment 
in patients with symptomatic AS and clinical improvement is 
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Fig. 2. Distribution of severity of diastolic function changes in TAVR and 
sAVR groups over time. Comparison between TAVR and sAVR at immedi-
ately after the procedure, p=0.018. Comparison between TAVR and sAVR 
at 3 months later, p=0.88. TAVR, transcatheter aortic valve replacement; 
sAVR, surgical aortic valve replacement; Pre, before the procedure.
Table 4. Changes in Diastolic Function over Time
 
TAVR sAVR
Pre Immediate 3 months Pre Immediate 3 months
HR (bpm) 72±16 73±15 68±13 62±15 83±13 73±15
E velocity (cm/s) 81.2±30.5 88.7±27.8* 93.3±30.4† 79.8±29.4 91±21.4* 81±23.1
A velocity (cm/s) 98.9±34.2 119.7±25.2* 105.5±22.5 98.3±22.7 98.7±22 101.7±28.0
Deceleration time (ms) 210±64 229±69* 239±54 205±45 204±61 261±80‡
e’ velocity (cm/s) 3.6±1.2 4.4±1.4* 3.9±0.9 3.7±1.4 4.5±1.5* 4.2±1.0
a’ velocity (cm/s) 6.9±2.5 6.7±2.1 6.7±1.9 7.2±1.7 6.0±2.1 7.0±2.6
E/e’ ratio 24.6±12.9 20±9.5* 23.9±7.8 21.5±9.4 20±6.4 20.7±7.0
RV systolic pressure (mm Hg) 38.4±17.2 34±12.4* 31.6±9.9 32.2±11.7 30±6.8 29.7±7.5
TAVR, transcatheter aortic valve replacement; sAVR, surgical aortic valve replacement; HR, heart rate; E/e’, E wave to e’ ratio; RV, right ventricle. 
Data are presented as means±standard deviations. 
*Effect between pre-procedure and immediately after procedure: p<0.05, †Effect between immediate procedure and after 3 months: p<0.05, ‡Significant difference 
only after 3 months: p<0.05
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expected in patients undergoing sAVR, diastolic stiffness along 
with relaxation normalization are recognized in late follow-
up.24 In our study, immediately after sAVR, patients also showed 
improvements in E and e' velocity, but no increase in DT and 
no decrease in E/e' ratio. These effects reflected the change in 
diastolic function grade immediately after the procedure. As a 
result, only 11% of the sAVR patients improved by at least one 
grade compared with TAVR (47%). The mean heart rate was 
faster in the sAVR group than in the TAVR group (83±13 vs. 73± 
15 bpm, p=0.003), and pleural effusion and pulmonary edema 
were more prevalent. After 3 months, the diastolic function dis-
tribution in the sAVR group was comparable to that in the TAVR 
group. A previous study showed that while TAVR did not influ-
ence RV function, it worsened in patients undergoing sAVR.25 
RSVP did not deteriorate in our sAVR patients, although this 
does not indicate a lack of RV function deterioration, because 
we did not measure RV function, such as fractional area change 
and tricuspid annular plane systolic excursion. In sum, favor-
able effects on LV diastolic function could play a major part in 
reducing postoperative complications, such as pulmonary in-
sufficiency, continued mechanical ventilation, renal insuffi-
ciency, myocardial dysfunction with demand for inotropes, 
and lengthened hospitalization, thus positively influencing the 
reported favorable short-term morbidity and mortality rates of 
surgery.26 In contrast, for patients allocated to sAVR, limited as-
sumptions can be made. The normalization of LV diastolic 
function24 and improvements in ejection fraction, volumes, and 
hypertrophy have been observed in long-term follow-up,27 
whereas short-term results appear to be limited by the effects 
of extracorporeal circulation, positive inotropic drug adminis-
tration, and the existence of paradoxical septum.
Immediately after valve replacement, no significant interval 
change was found in RWT or LVMI, which are representative 
of ventricular remodeling parameters, in either of the study 
groups. The sAVR group had more profound LV mass regres-
sion after 3 months. Early regression in mass and reverse LV 
remodeling after TAVR were reported in a previous study.28 In 
addition, previous 6-month follow-up TTE studies demonstrat-
Fig. 3. Changes in diastolic function parameters over time. (A) Serial change of E velocity. (B) Serial change of e' velocity. (C) Serial change of E/e' ratio. (D) 
Serial change of RVSP. The error bars represent one standard deviation. E/e’: E velocity to e’ ratio; RVSP: right ventricular systolic pressure; TAVR: trans-
catheter aortic valve replacement; sAVR: surgical aortic valve replacement; Pre: before the procedure; mo: months.
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ed that TAVR results in LV and LA reverse remodeling and ame-
liorates LV relaxation and LA filling pressure in patients with 
severe AS and concentric hypertrophy.29,30 However, in our 
study, LV mass regression occurred earlier, and LV mass tend-
ed to be lower immediately after the procedure than after 6 
months. LV mass regression can be explained by reduced LV 
afterload and concomitant change in LV wall thickness. Al-
though LVEDD, LVESD, and mitral regurgitation did not differ 
significantly between groups, smaller LVEDD and LVESD in 
the sAVR group, especially after 3 months, might be affected by 
less aortic regurgitation in sAVR than in TAVR, with more pa-
tients using diuretics frequently after surgery to manage pleu-
ral effusion and pulmonary edema. Other factors that could 
affect LV remodeling (e.g., hypertension, renal dysfunction, 
sex) and ventricular function warrant further study.
Limitations
This was a single-center study with a small number of patients 
and relatively short follow-up period. We found it difficult to 
find a matched surgical AVR group for head-to-head compar-
ison with TAVI group in the TAVI era among TAVI candidate pa-
tients who were old and at high risk. Accordingly, we enrolled 
sAVR patients during the same period with the criterion of over 
75 years of age for comparison with TAVR group. Because this 
study was not a randomized controlled trial, selection bias may 
be a factor due to patients with reduced EF not being included 
and patients with more advanced diastolic function being in-
cluded. Furthermore, this was principally an echocardiograph-
ic study, and we were unable to manifest differences in clini-
cal outcomes between subgroups, possibly due to differences 
in diastolic dysfunction grade. The potential impact on clinical 
outcomes must be evaluated in a larger prospective trial with 
a longer follow-up, and a multi-center, large number registry 
study will be need in the future.
Conclusion
Our results indicate that LV diastolic function improves 
more rapidly and immediately after TAVR despite higher 
baseline risk. In addition, noted improvements persisted for 
up to 3 months. Thus, in patients with severe AS with advanced 
Table 5. LA and LV Structural Changes over Time
 
TAVR sAVR
Pre Immediate 3 months Pre Immediate 3 months
Cardiac index (L/min/m2) 3.2±0.9 3.6±1.4 3.2±0.9 3.5±0.9 3.8±0.8 3.5±1.2
LVEDD (mm) 48.7±7.7 48.1±7.3 49±7.7 49±7.8 48±7.8 45.4±4.5†
LVESD (mm) 33.5±9.3 32.6±8.9 33±8.6 33±8 32.2±8.1 30±4.9†
IVST (mm) 12.8±3.8 12.7±2.9 12±2.2 12±1.5 12.2±1.4 11±1.9
LVPWT (mm) 11.9±1.6 11.8±2.9 11.2±1.8 11.8±2.2 11.4±1.0 11±0.9
RWT 0.49±0.13 0.51±0.11 0.48±0.1 0.49±0.1 0.48±0.1 0.48±0.1
LVMI (g/m2) 159±48 156±50 148±48† 146±41 141±41 125±29†
LAVI (mL/m2) 43.3±16.7 42.8±17.2 44.2±16.1 51.1±22 45.9±17.4* 46.3±21.9 
TAVR, transcatheter aortic valve replacement; sAVR, surgical aortic valve replacement; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic di-
ameter; LVESD, left ventricular end-systolic diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; RWT, relative wall 
thickness; LVMI, left ventricular mass index; LAVI, left atrial volume index.
Data are presented as means±SDs. 
*Effect between pre-procedure and immediate procedure: p<0.05, †Significant difference only after 3 months: p<0.05
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diastolic dysfunction and at higher surgical risk, TAVR might 
be a better option than surgery and, potentially, the standard of 
care for severely symptomatic inoperable patients or for those 
at high risk of non-cardiovascular mortality after conventional 
surgery. These results might explicate the remarkable clinical 
improvement in improvements in advanced diastolic dys-
function immediately after the TAVR procedure than sAVR.
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